Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.65 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449149 | 1.00 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL12740838 | 1.00 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL22792019 | 0.90 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1447948 | 0.89 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL16605 | 0.89 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1447946 | 0.89 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31045900 | 0.89 | GPR119 (0.61) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL12089264 | 0.88 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL31713163 | 0.88 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL31045911 | 0.87 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | GPR119 1/4885SMARCA2 2093/4885SMARCA4 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.